Griepvaccin biedt toch minder
bescherming dan gedacht
A Group Health study in the Aug. 2 Lancet
fuels the growing controversy over how well the flu vaccine protects seniors. The study of
more than 3,500 Group Health patients age 65 found no link between flu vaccination and
risk of pneumonia during three flu seasons. This largest case-control study of flu vaccine
in the elderly suggests the flu vaccine doesn't protect seniors as much as has been
thought.
Nederlandse en Amerikaanse wetenschappers
zijn het oneens over het effect van de jaarlijkse injectie bij bejaarden. Ouderen
vaccineren tegen wintergriep helpt, klonk het donderdag vanuit Maastricht. Amerikaanse
epidemiologen denken daar anders over. Het griepvaccin, schrijven ze in The Lancet,
beschermt oude mensen niet tegen longontsteking. Het is een nieuw hoofdstuk in een ruzie
onder vaccin-experts over het nut van de griepprik. Miljoenen Nederlanders krijgen die
jaarlijks. De discussie begon donderdag met een persbericht van de Universiteit
Maastricht.
Meer twijfels over de
effectiviteit en veiligheid van het griepvaccin
Volgens epidemiloog Dr Tom
Jefferson heeft het zogenaamde inactieve griepvaccin voor ouderen weinig zin. Hij bekeek
de studies die er reeds zijn gedaan naar bijvoorbeeld bezoek aan ziekenhuizen, afwezigheid
op het werk, dood of complicaties door griep en zag dat het weinig effect had. Ook
tonen de studies weinig bewijs van de veiligheid van de vaccins. Ook Dr Jefferson van het
onafhankelijke Cochrane instituut die studies controleert spreekt van weinig tot geen
effect en noemt ook de slechte kwaliteit van de gedane studies. http://www.lse.co.uk/ShowStory.asp?story=WR2630459N
No Evidence Flu Jabs Work for
Under-2s - Study. There is no evidence that vaccinating children under 2 years old against
influenza reduces deaths or complications from the illness, researchers said on Friday.
They reviewed 25 studies that looked at the impact of vaccines in cutting the
number of cases of influenza and its symptoms in children up to 16. "Immunization of
very young children is not lent support by our findings," said Dr Tom Jefferson, of
the Cochrane Vaccines Field in Rome, part of the international Cochrane Collaboration that
evaluates medical research. "We recorded no convincing evidence that vaccines can
reduce mortality, admissions, serious complications and community transmission of
influenza," he added in a report in The Lancet medical journal. http://www.askdrsears.com/news/headlines0205.asp
Video - Eye On The Flu Shot
the ingredients poisoning your children
Voordelen van griepvaccins erg
overdreven
Mortality benefits of influenza
vaccination in elderly people: an ongoing controversy
Influenza vaccination policy in most
high-income countries attempts to reduce the mortality burden of influenza by targeting
people aged at least 65 years for vaccination. However, the effectiveness of this strategy
is under debate. Although placebo-controlled randomised trials show influenza vaccine is
effective in younger adults, few trials have included elderly people, and especially those
aged at least 70 years, the age-group that accounts for three-quarters of all
influenza-related deaths. Recent excess mortality studies were unable to confirm a decline
in influenza-related mortality since 1980, even as vaccination coverage increased from 15%
to 65%. Paradoxically, whereas those studies attribute about 5% of all winter deaths to
influenza, many cohort studies report a 50% reduction in the total risk of death in
winter—a benefit ten times greater than the estimated influenza mortality burden. New
studies, however, have shown substantial unadjusted selection bias in previous cohort
studies. We propose an analytical framework for detecting such residual bias. We conclude
that frailty selection bias and use of non-specific endpoints such as all-cause mortality
have led cohort studies to greatly exaggerate vaccine benefits. The
remaining evidence base is currently insufficient to indicate the magnitude of the
mortality benefit, if any, that elderly people derive from the vaccination programme.
Nieuw immunotoxisch effect
Thimerosal (zit in vele griepvaccins) verandert werking van dendrietcellen
Thimerosal, een conserveermiddel op basis
van kwik, dat oa in de meerderheid van griepvaccins wordt gebruikt is al eerder gelinkt
aan neurotoxische effecten. Nieuw onderzoek onthult nu ook het effect op het immuunsysteem
doordat het de manier waarop dendrietcellen reageren op biochemische signalen verandert.
Deze cellen spelen een belangrijke rol bij infecties. Eén geactiveerde dendriet cel kan
al honderden T-cellen op de indringer afsturen, maar dan moet de cel dus wel goed
reageren.
Bij concentraties van 200 ppb gingen deze
dendriet cellen zelfs dood!. Het doorlopende gebruik van thimerosal in (griep)vaccins en
andere produkten moet dus reden zijn voor meer onderzoek naar deze immuuntoxische effect
van dit middel en het aandeel ethylkwik daarbij.
Meer dan 1 miljoen kinderen
krijgen nog steeds kwik vaccins:
de griepprik !
The Age of Autism: Mercury creeps back in
New calculations suggest children today
can be exposed to more than half the mercury that was in vaccines in the 1990s, even
though manufacturers began phasing it out in 1999. Adjusted for a child's body weight at
the time of the shots, there's virtually no reduction at all, according to this analysis.
The source: Flu vaccines, which have been
recommended for millions more kids over 6 months old and pregnant women in the past few
years. Most of those shots still contain the mercury-based preservative called thimerosal
that some fear is behind a huge rise in autism diagnoses. "It's been under the radar
and it's allowed health officials to say, 'We've taken it out of all the childhood
vaccines,'" said Dr. David Ayoub, an Illinois anti-thimerosal activist who put the
data together along with Maryland researchers David Geier and Dr. Mark Geier. "They
don't consider influenza one of the mandated childhood vaccines yet," Ayoub said. But
because the Centers for Disease Control and Prevention now recommends flu shots for all
pregnant women and all children between 6 months and age 5, doctors routinely give them.
Missing the Flu Diagnosis in Kids
Just Another Excuse for a Vaccine
Flu infections in young children are
often missed by doctors, a new study reports. The diagnosis was missed in four out of five
preschoolers treated for flu symptoms at a doctor's office or emergency room, and in about
three-quarters of those who were hospitalized. During the four-year study, the researchers
conducted their own lab tests on children who saw doctors for symptoms such as cough,
runny nose
and fever. Only 28 percent of hospitalized flu cases and 17 percent of those who visited a
doctor or emergency room were diagnosed with the flu. Other diagnoses included asthma,
pneumonia and general viral illness.
The researchers, two of which received
grant support and consulting fees from MedImmune Inc., the maker of a spray flu vaccine,
said using a rapid flu test more often could detect more cases of flu and help prevent its
spread. Further, one-third of the children could have taken a drug like
Tamiflu to ease their symptoms.
The results were presented to a Centers
for Disease Control and Prevention (CDC) panel, which recommended expanding 2006 flu shots
for children between the ages of 2 and 5; flu shots are already recommended for children
aged 6-23 months.
